MedTrace Logo

Platelet Aggregation in COVID-19 Patients

NCT06097429 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2023-10-24

No results posted yet for this study

Summary

Context: Hypercoagulable state associated with COVID-19 is one of the pathologic events that noticed in different waves of COVID-19 pandemics and leads to serious consequences in mortality and morbidity Aim: To evaluate platelet aggregation using light-transmission aggregometry and adenosine diphosphate (ADP) as an agonist in COVID-19 patients.

Settings and design: This was prospective cross-sectional study. Patients and methods: Seventy-five individuals were enrolled in this study and divided into two groups, 50 patients with PCR-positive COVID-19 as study group and 25 apparently healthy individual as a control group. All individuals were subjected to full clinical evaluation, CT-chest, laboratory investigations: CBC, INR, LDH, CRP, serum ferritin and platelet aggregation evaluation using light-transmission aggregometry and adenosine diphosphate (ADP) as an agonist

Conditions

Interventions

DIAGNOSTIC_TEST

blood sample for platelet aggregation

evaluate platelet aggregation using light-transmission aggregometry and adenosine diphosphate (ADP)

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • rehab Ah elmorsey, MD · Mansoura University, chest medicine departmenr

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2022-01-01
Completion
2022-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06097429 on ClinicalTrials.gov